Sangui BioTech International Inc.
- WKN: 906757
- ISIN: US80105B1017
- Land: Germany
Nachricht vom 09.10.2019 | 14:53
Sangui BioTech International Inc.: Sales of USD 88,001 in fiscal year 2019
DGAP-News: Sangui BioTech International Inc.
/ Key word(s): Annual Results
As operating expenses increased USD 140,501 or 40% to USD 425,636 during the period, operating loss increased USD 129,590 to USD 337,635 from the prior year. The cause of this development was, among others, the restructuring costs associated with the closure of the Witten site on 30/06/2019.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.